Kenvue Inc. (NYSE:KVUE) Shares Sold by Crestwood Advisors Group LLC

Crestwood Advisors Group LLC trimmed its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 1.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,459,631 shares of the company's stock after selling 25,491 shares during the period. Crestwood Advisors Group LLC owned approximately 0.08% of Kenvue worth $35,002,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after purchasing an additional 4,034 shares during the last quarter. Starboard Value LP bought a new stake in shares of Kenvue during the 4th quarter worth approximately $467,864,000. TrueMark Investments LLC lifted its stake in shares of Kenvue by 9.3% during the 4th quarter. TrueMark Investments LLC now owns 190,595 shares of the company's stock worth $4,069,000 after acquiring an additional 16,161 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in shares of Kenvue during the 1st quarter worth approximately $413,000. Finally, Cooper Investors PTY Ltd. lifted its stake in shares of Kenvue by 39.7% during the 1st quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock worth $20,577,000 after acquiring an additional 244,043 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KVUE. Bank of America decreased their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Redburn Atlantic started coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. Barclays reduced their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Tuesday, July 15th. UBS Group cut their price target on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Finally, Citigroup dropped their target price on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.71.

Kenvue Stock Performance

KVUE traded down $0.06 on Thursday, reaching $22.48. 2,532,987 shares of the stock were exchanged, compared to its average volume of 17,244,086. The company's 50-day moving average price is $22.08 and its 200 day moving average price is $22.32. Kenvue Inc. has a fifty-two week low of $18.10 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a market capitalization of $43.13 billion, a PE ratio of 40.85, a PEG ratio of 3.78 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period in the previous year, the company posted $0.28 earnings per share. Kenvue's revenue for the quarter was down 3.9% on a year-over-year basis. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.